Author(s): Patel G, Bonomo RA
Antimicrobial resistance in hospital and community-onset bacterial infections is a significant source of patient morbidity and mortality. In the past decade, we have witnessed the increasing recovery of carbapenem-resistant Gram-negative bacteria. For many isolates, carbapenem resistance is due to the production of carbapenemases, β-lactamases that can inactivate carbapenems and frequently other β-lactam antibiotics. Currently, these enzymes are mainly found in three different β-lactamase classes (class A, B and D). Regardless of the molecular classification, there are few antimicrobials available to treat infections with these organisms and data regarding agents in development are limited to in vitro studies. This article focuses on the epidemiology of carbapenemase-producing Gram-negative bacteria. We also review available agents and those in development with potential activity against this evolving threat.
Referred From: http://www.tandfonline.com/doi/full/10.1586/eri.11.28
Author(s): Queenan AM, Bush K
Author(s): Doumith M, Ellington MJ, Livermore DM, Woodford N
Author(s): Walsh TR
Author(s): Bradford PA
Author(s): Sidjabat HE, Silveira FP, Potoski BA, Abu-Elmagd KM, Adams- Haduch JM, et al.
Author(s): Fallah F, Hakemi Vala M, Hashemi A, Shams S
Author(s): Nordmann P, Naas T, Poirel L
Author(s): Haji Hashemi B, Farzanehkhah M, Dolatyar A, Imani M, Farzami MR, et al.
Author(s): Center for disease control and Prevention
Author(s): Patzer JA, Dzierzanowska D
Author(s): Lee K, Yong D, Yum JH, Lim YS, Bolmstrom A, et al.
Author(s): Paterson DL, Hujer KM, Hujer AM, Yeiser B, Bonomo MD, et al.
Author(s): Boyd DA, Tyler S, Christianson S, McGeer A, Muller MP, et al.
Author(s): Monstein HJ, Östholm-Balkhed A, Nilsson MV, Nilsson M, Dornbusch K, et al.